Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFRTargeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis

Ontario Health Technology Assessment Series

Volumn 10, Issue 24, 2010, Pages 1-48

 

^a ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84939781286     PISSN: 19157398     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Canadian Cancer Society's Steering Committee. Canadian cancer statistics 2009 [Internet]. Toronto: Canadian Cancer Society. 2009 Apr [cited: 2010 Mar 3]. 124 p. Available from: http://tinyurl.com/d885qh
2. Franceschi S, Bidoli E. The epidemiology of lung cancer. Ann Oncol 1999; Suppl 5(10):S3-S6.
3. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J 2009; 33(6): 1485-97.
4. Bulzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G et al. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70(5): 1102-10.
5. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2010; 128(1):452-62.
6. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al. Changing epidemiology of small-cell lung cancer in the united states over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24(28):4539-44.
7. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2009; 346(2):92-8.
8. Cohen S. Purification of the receptor for epidermal growth factor from A-431 cells: its function as a tyrosyl kinase. Methods Enzymol 1983;(99):379-87.
9. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284(1):31-53.
10. Wells A. Molecules in focus: EGF receptor. Int J Biochem Cell Biol 1999; 31(6):637-43.
11. Alexander L. EGF receptor as a therapeutic target. Lung Cancer 2003; 41(Suppl. 1):S9-14.
12. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors. Semin Oncol 2003; 1(Suppl. 1):3-11.
13. Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 2008; 5(4):209-17.
14. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2009; 358(11): 1160¬74.
15. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21(12):2237-46.
16. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290(16):2149-58.
17. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol 2004; 22(16):3238-47.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21):2129-39.
19. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676): 1497-500.
20. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12(24):7232-41.
21. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006; 11(3): 190-8.
22. John T, Liu G, Tsao M. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009; 28(S1):S14-S23.
23. Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 2005; 16(4):538-48.
24. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26(6):983-94.
25. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353(2): 133-44.
26. Parra HS, Cavina R, Latteri F, Zucali PA, Campagnoli E, Morenghi E et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004; 91(2):208-12.
27. Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 2008; 112(5): 1114-21.
28. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Franklin WA, Dziadziuszko R, Thatcher N et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24(31):5034-42.
29. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-32.
30. Clark GM, Zborowski DM, Culbertson JL, Whitehead M, Savoie M, Seymour L et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 2006; 1(8):837-46.
31. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007; 18(4):752-60.
32. Zhu CQ, da Cunha SG, Ding K, Sakurada A, Cutz JC, Liu N et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26(26):4268-75.
33. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372(9652):1809-18.
34. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Di Maria MV, Veve R, Bremnes RM et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21(20):3798-807.
35. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23(28):6829-37.
36. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97(9):643-55.
37. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005; 23(22):5007-18.
38. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005; 23(28):6838-45.
39. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23(31): 8081-92.
40. Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 2006; 12(10):3078-84.
41. Sone T, Kasahara K, Kimura H, Nishio K, Mizuguchi M, Nakatsumi Y et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer 2007; 109(9):1836-44.
42. Ichihara S, Toyooka S, Fujiwara Y, Hotta K, Shigematsu H, Tokumo M et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small- cell lung cancer. Int J Cancer 2007; 120(6): 1239-47.
43. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454): 1490.
44. Goodman C. Literature searching and evidence interpretation for assessing health care practices. Stockholm, Sweden: The Swedish Council on Technology Assessment in Health Care. 1993 81 p. SBU-Report No 119E.
45. Blue Cross and Blue Shield Association. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer [Internet]. Chicago: Blue Cross and Blue Shield Association. 2007 [cited: 2010 Jun 3]. 21 p. Volume 22, No. 6. Available from: http://www.bcbs.com/blueresources/tec/vols/22/2206.pdf
46. Mujoomdar M, Moulton K Spry C. Epidermal growth factor receptor mutation analysis in advanced non-small cell lung cancer: A review of the clinical effectiveness and guidelines [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2010 28 p. Available from: http://www.cadth.ca/media/pdf/M0017 EGFR Testing for NSCLC e.pdf
47. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10):947-57.
48. Lee J, Park K, Kim S, et al. Lee,JS; Park,K; Kim,SW; et al. A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. Presented at 13th World Conference on Lung Cancer; July 31 to August 4th, 2009; San Francisco, CA. Pres. 4. 2009
49. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362(25):2380-8.
50. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11(2): 121-8.
51. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26(9):1472-8.
52. Schneider CP, Heigener D, Schott-von-Romer K, Gutz S, Laack E, Digel W et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 2008; 3(12): 1446-53.
53. Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008; 14(12):3867-74.
54. Ahn MJ, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 2008; 14(12):3860-6.
55. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28(5):744-52.
56. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23(4):857-65.
57. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361(10):958-67.
58. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010; 16(1):291-303.
59. De LA, Normanno N. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr Drug Targets 2010; 11(7):851-64.
60. Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 2010; 102(5):298-306.
61. Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small- cell lung cancer. J Clin Oncol 2002; 20(5):1344-52.
62. Statistics Canada. 2006 Canada Census [Internet]. Statistics Canada. 2006 [cited: 2010 Dec 16]. Available from: http://www.fin.gov.on.ca/en/economy/demographics/census/cenhi06-Lhtml
63. Statistics Canada. Canadian Cancer Registry [Internet]. Ottawa: Statistics Canada. 2007 [cited: 2010 Dec 16]. Available from: http://www.statcan.gc.ca/cgi-bin/imdb/p2SV.pl?Function=getSurvey&SurvId=3207&SurvVer=0&InstaId=15214&InstaVer=10&SDDS=3207&lang=en&db=imdb&adm=8&dis=2
64. Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21(17):3207-13.
65. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52(2): 155-63.
66. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17(1): 12-8.
67. Ceribelli A, Gridelli C, De MF, Fabi A, Gamucci T, Cortesi E et al. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 2003; 98(2):337-43.
68. Chang JW, Tsao TC, Yang CT, Lin MC, Cheung YC, Liaw CC et al. A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer. Chang Gung Med J 2008; 31(6):559-66.
69. Crino L, Scagliotti GV, Ricci S, De MF, Rinaldi M, Gridelli C et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17(11):3522-30.
70. Grigorescu A, Ciuleanu T, Firoiu E, Muresan DR, Teodorescu G, Basson BR. A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung Cancer 2007; 57(2): 168-74.
71. Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ et al. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial. Lung Cancer 2008; 62(3):334-43.
72. Kim JH, Kim SY, Jung KH, Park K, Suh CW, Lim HY et al. Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. Lung Cancer 2006; 52(1):75-81.
73. Liao ML, Zhu YZ, Li LY, Wan HY, Yu SY, Hall B et al. Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial conducted in Chinese patients with nonsmall cell lung cancer. Chin Med J (Engl) 2008; 121(10): 892-7.
74. Martoni A, Marino A, Sperandi F, Giaquinta S, Di FF, Melotti B et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005; 41(1):81- 92.
75. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18(2):317-23.
76. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006; 24(9): 1428-34.
77. Pereira JR, Fein L, Del GA, Blajman CR, Richardet E, Schwartsmann G et al. Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. Lung Cancer 2007; 58(1):80-7.
78. Reck M, von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non¬small-cell lung cancer: AVAil. J Clin Oncol 2009; 27(8): 1227-34.
79. Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes PA et al. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. Cancer 2000; 89(8): 1714-9.
80. Rinaldi M, Crino L, Scagliotti GV, Mosconi AM, De MF, Gridelli C et al. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol 2000; 11(10): 1295-300.
81. Rubio JC, Vazquez S, Vazquez F, Amenedo M, Firvida JL, Mel JR et al. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 2009; 64(2):379-84.
82. Sandler AB, Nemunaitis J, Denham C, von PJ, Cormier Y, Gatzemeier U et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18(1): 122-30.
83. Scagliotti GV, Parikh P, von PJ, Biesma B, Vansteenkiste J, Manegold C et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26(21):3543-51.
84. Syrigos KN, Vansteenkiste J, Parikh P, von PJ, Manegold C, Martins RG et al. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin- gemcitabine in advanced non-small-cell lung cancer. Ann Oncol 2010; 21(3):556-61.
85. Wachters FM, Van Putten JW, Kramer H, Erjavec Z, Eppinga P, Strijbos JH et al. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. Br J Cancer 2003; 89(7): 1192-9.
86. Zatloukal P, Petruzelka L, Zemanova M, Kolek V, Skrickova J, Pesek M et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003; 41(3):321-31.
87. Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low- dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 2009; 4(9): 1148-55.
88. Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006; 17(3):467-72.
89. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006; 129(4): 1031-8.
90. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006; 17(4):401-9.
91. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005; 16(1):90-6.
92. Gridelli C, Gallo C, Di MM, Barletta E, Illiano A, Maione P et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004; 91(12): 1996-2004.
93. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De MF, von PJ et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22(9):1589-97.
94. Jones S, Thompson D, Barton J, Patton J, Shipley D, Greco FA et al. A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. Clin Lung Cancer 2008; 9(3): 154-9.
95. Krzakowski M, Ramlau R, Jassem J, Szczesna A, Zatloukal P, von PJ et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol 2010; 28(13):2167-73.
96. Lai CL, Tsai CM, Chiu CH, Wang GS, Su WJ, Chen YM et al. Phase II randomized trial of tri¬weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol 2005; 35(12):700-6.
97. Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum- based chemotherapy. Clin Cancer Res 2010; 16(4): 1307-14.
98. Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, von PJ et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008; 98(10): 1608-13.
99. Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, Gaglia A et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non¬small-cell lung cancer: a randomized phase II trial. Ann Oncol 2005; 16(2):294-9.
100. Quoix E, Lebeau B, Depierre A, Ducolone A, Moro-Sibilot D, Milleron B et al. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer. Ann Oncol 2004; 15(1):38-44.
101. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005; 23(33):8389-95.
102. Wachters FM, Groen HJ, Biesma B, Schramel FM, Postmus PE, Stigt JA et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 2005; 92(1): 15-20.
103. Cullen MH, Zatloukal P, Sorenson S, Novello S, Fischer JR, Joy AA et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008; 19(5):939-45.
104. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non¬small cell lung cancer. J Thorac Oncol 2009; 4(8): 1002-9.
105. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000; 83(4):447-53.
106. Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9(8): 1453-61.
107. Goss G, Ferry D, Wierzbicki R, Laurie SA, Thompson J, Biesma B et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small- cell lung cancer and poor performance status. J Clin Oncol 2009; 27(13):2253-60.
108. Kennedy W, Reinharz D, Tessier G, Contandriopoulos AP, Trabut I, Champagne F et al. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer. Pharmacoeconomics 1995; 8(4):316-23.
109. Neninger VE, de la TA, Osorio RM, Catala FM, Bravo I, Mendoza del PM et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008; 26(9):1452-8.
110. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6(4):633-41.
111. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27(3):145-57.
112. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18(10):2095-103.
113. Thatcher N, Chang A, Parikh P, Rodrigues PJ, Ciuleanu T, von PJ et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366(9496):1527-37.
114. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24(1):17-24.
115. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008; 6:84.
116. Canadian Cancer Society. Lung cancer statistics [Internet]. Canadian Cancer Society. 2010 [cited: 2010 Dec 16]. Available from: http://www.cancer.ca/canada-wide/about%20cancer/cancer%20statistics/stats%20at%20a%20glance/lung%20cancer.aspx?sclang=en
117. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75(1 Suppl): 191-202.